Opus Genetics (IRD) Non-Current Assets (2010 - 2026)
Opus Genetics (IRD) posted quarterly Non-Current Assets of $186000.0 for Q1 2026, down 22.18% year-over-year from $239000.0 in Q1 2025, and down 6.53% quarter-over-quarter from $199000.0 in Q4 2025.
Opus Genetics (IRD) Non-Current Assets (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Non-Current Assets for 17 consecutive years, with $186000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 22.18% year-over-year to $186000.0; the TTM figure through Mar 2026 stood at $823000.0 (up 67.62% YoY), while the FY2025 annual figure was $199000.0, down 21.03% from the prior year.
- Non-Current Assets declined to $186000.0 in Q1 2026 per IRD's latest filing, from $199000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $252000.0 in Q4 2024 and bottomed at $3000.0 in Q3 2023.
- Historically, Non-Current Assets has averaged $104307.7 across 5 years, with a median of $9000.0 in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 57.14% — and 2025, when it fell 21.03%.
- Opus Genetics' Non-Current Assets stood at $6000.0 in 2022, then slumped by 50.0% to $3000.0 in 2023, then surged by 8300.0% to $252000.0 in 2024, then retreated by 21.03% to $199000.0 in 2025, then fell by 6.53% to $186000.0 in 2026.
- Business Quant data shows IRD's Non-Current Assets at $186000.0 in Q1 2026, $199000.0 in Q4 2025, and $212000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 272,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 272,000.00 |
| Mar 31, 2026 | 186,000.00 |
| Dec 31, 2025 | 199,000.00 |
| Sep 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 252,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | 6,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 13,000.00 |
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 180,564.00 |